KIVU BIOSCIENCE
Investment area
Venture Investments
Region
North America
Date of investment
October 2024
Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its first two lead candidates to clinical trials expected to begin in 2025. The company is headquartered in San Francisco, CA.